At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 93 participants across 15 sites.
Detailed Summary
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Hoosier Cancer Research Network
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartMar 2015
Primary CompletionAug 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJan 22, 2015
Enrollment StartMar 9, 2015
Primary CompletionAug 10, 2020
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.4 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.